Ocugen Inc. Common Stock (OCGN)

About OCGN

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the tre…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

116

Website

ocugen.com/

Fundamentals

1-day range

$1.32$1.37

Market cap

$423.89M

P/E (trailing)

—

P/E (forward)

-4.95

EPS (trailing)

$-0.20

Dividend yield

—

Beta

2.22

Avg. volume

6.32M

Dividend pay date

September 30, 2019

Forecasts

6 analyst ratings

Ocugen Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• OCGN

  Ocugen Inc. Common Stock

  $1.32

  ▼ 3.65%
  Market cap $423.89MP/E —
  $1$2.73
• STRO

  Sutro Biopharma Inc. Common Stock

  $20.42

  ▼ 4.18%
  Market cap $415.92MP/E —
  $7.15$43.85
• CABA

  Cabaletta Bio Inc. Common Stock

  $3.11

  ▼ 7.99%
  Market cap $438.62MP/E —
  $1.4$4.23
• KYTX

  Kyverna Therapeutics Inc. Common Stock

  $8.36

  ▼ 3.24%
  Market cap $456.57MP/E —
  $3.55$13.67
• CCCC

  C4 Therapeutics Inc. Common Stock

  $3.85

  ▼ 6.10%
  Market cap $386.99MP/E —
  $1.69$5.17
• XFOR

  X4 Pharmaceuticals Inc. Common Stock

  $4.05

  ▼ 4.26%
  Market cap $385.77MP/E 2.95
  $2.8$4.83
• PROK

  ProKidney Corp. Class A Ordinary Shares

  $1.84

  ▲ 1.10%
  Market cap $471.21MP/E —
  $1.3$3.48

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/6/2026
• Ocugen (NASDAQ:OCGN) Falls on Mixed Q2 Results as Revenue Beat Offsets Wider Loss
  ChartMill · 8/6/2026
• Ocugen Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $1.488M Beat $888.833K Estimate
  benzinga · 8/6/2026
• Ocugen Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $1.488M Beat $888.833K Estimate
  Benzinga · 8/6/2026

• Treerita Essalima Johnson-Greene · June 15, 2026 · Buy

  21.0K @ $1.23
• Kompella Uday · June 11, 2026 · Grant

  170.1K
• Chandrasekhar Satishchandran · June 11, 2026 · Grant

  170.1K
• Kirsten Castillo · June 11, 2026 · Grant

  170.1K
• Junge Zhang · June 11, 2026 · Grant

  170.1K
• Coleman Blaise · June 11, 2026 · Grant

  170.1K
• Junge Zhang · April 1, 2026 · Option Exercise

  66.9K @ $1.42
• Junge Zhang · April 1, 2026 · Option Exercise

  112.2K @ $0.46
• Junge Zhang · April 1, 2026 · Option Exercise

  15.0K @ $0.51

Institutional Ownership

March 31, 2026

Total shares held

110.69M

Total value held

$198.39M

Institutional holders

132